Argent BioPharma Cuts US$5.5m Debt with Splash Licensing Deal, Advances Veterinary Assets
Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.
- US$5.5 million secured debt forgiven via Splash Beverage licensing deal
- Acquisition of 48% interest in CannPal Animal Therapeutics finalised
- Positive Phase 2C results advance veterinary CPAT-01 towards Phase 3
- Operating cash outflows of A$600,000 with closing cash at A$141,000
- Additional A$700,000 funding drawn from convertible securities facility
Splash Beverage Deal Removes US$5.5m Secured Debt
Argent BioPharma (ASX:RGT) has struck a significant global licensing agreement for its flagship cannabinoid therapy, CannEpil®, with Splash Beverage Group (NYSE American: SBEV). The deal extinguishes US$5.5 million of secured convertible notes owed to Mercer Street Global Opportunity Fund, effectively wiping out a major liability without issuing new shares.
Under the arrangement, Argent retains full ownership of CannEpil®’s intellectual property and continues EU-GMP manufacturing on a cost-plus basis, while securing a 15% royalty on net revenues for up to ten years or until patent expiry. Splash Beverage assumes responsibility for funding and managing the costly US clinical and regulatory pathway, including Phase I and II trials and an FDA New Drug Application filing. This transfer of financial risk and operational burden marks a strategic de-risking ahead of Argent’s planned US national exchange listing.
Completion of CannPal Acquisition Broadens Neuro-Immune Pipeline
During the quarter, Argent completed the acquisition of AusCann Group Holdings’ 48% stake in CannPal Animal Therapeutics and its Neuvis® drug delivery platform. CannPal’s lead veterinary asset, CPAT-01, is an advanced-stage (Phase 3) cannabinoid therapy targeting osteoarthritis pain in dogs, offering potential near-term commercialisation.
The Neuvis® platform option adds formulation flexibility and lifecycle management to Argent’s broader pipeline. This acquisition aligns with Argent’s neuro-immune strategy, expanding its footprint across human and veterinary indications and supporting its ambitions for a US national exchange listing.
Positive Phase 2C Data Propel CPAT-01 Towards Phase 3
CannPal’s Phase 2C dose confirmation study for CPAT-01 demonstrated a statistically significant reduction in osteoarthritis pain in aged beagles without serious adverse events. These results support progression to a Phase 3 pilot field study designed to bridge into commercial-use populations ahead of a pivotal registration trial.
CannPal is pursuing partner-led funding for this next stage and has initiated due diligence with several animal health sector prospects, signalling industry interest in the veterinary cannabinoid space.
Financials and Corporate Updates
Argent reported operating cash outflows of A$600,000 for the quarter, with staff costs at A$100,000 and research and development expenses at A$48,000. The company closed the quarter with A$141,000 in cash but subsequently drew down an additional A$700,000 under its A$11 million convertible securities financing facility with C/M Capital Master Fund and WVP Emerging Manager Onshore Fund.
On the corporate front, Andrew Chapman joined the board as Executive Director following the CannPal acquisition but transitioned to Non-Executive Director after quarter-end, with CEO Roby Zomer resuming Executive Chairman duties.
Bottom Line?
Argent’s debt-for-licensing deal and veterinary asset acquisition strategically reduce risk and broaden its pipeline, but clinical and regulatory milestones remain critical to watch.
Questions in the middle?
- How will Splash Beverage’s management of US clinical trials impact CannEpil®’s regulatory timeline?
- What terms might emerge from CannPal’s partner-led funding discussions for Phase 3 development?
- Can Argent leverage its expanded neuro-immune portfolio to attract further investment ahead of its US listing?
